Welcome to our dedicated page for Acuren SEC filings (Ticker: TIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Titan International鈥檚 filings dig deep into what drives the world鈥檚 tractors, combines and haul trucks鈥攐ff-the-road wheels, tires and undercarriage systems built for punishing fields and mines. That industry complexity shows up in equally dense disclosures about steel and rubber costs, farm-equipment cycles, and the Goodyear Farm Tires licensing agreement.
Finding those details inside a 300-page annual report or a mid-quarter 8-K is tough. Our AI-powered engine turns Titan International SEC filings into plain-English insights. Whether you need the Titan International insider trading Form 4 transactions alert, a quick read of the latest Titan International quarterly earnings report 10-Q filing, or context around a sudden plant shutdown revealed in an 8-K, the platform delivers real-time updates straight from EDGAR鈥攁lready summarized, tagged and searchable.
Here鈥檚 what you can uncover in seconds:
- 10-K & 10-Q 鈥� Segment revenue swings, commodity-price sensitivities, and foreign-exchange impacts, all presented in an Titan International annual report 10-K simplified format.
- Form 4 鈥� Titan International Form 4 insider transactions real-time to monitor when executives buy wheels for their own portfolios.
- Proxy Statement 鈥� Clarity on Titan International proxy statement executive compensation against cyclical performance targets.
- 8-K 鈥� Titan International 8-K material events explained so you know instantly when a plant re-tooling or royalty amendment hits the tape.
Use these AI-powered summaries to compare quarter-over-quarter margin trends, follow Titan International earnings report filing analysis, or simply save hours understanding Titan International SEC documents with AI. Complex filings become actionable insights鈥攏o heavy equipment required.
On 1 July 2025, venture fund 5AM Opportunities I, L.P. filed a Form 144 indicating its intent to sell up to 6,422 common shares of Entrada Therapeutics, Inc. (NASDAQ: TRDA) through TD Securities (USA) LLC. The proposed transaction is valued at roughly USD 45,737 and represents only 0.02 % of Entrada鈥檚 37.95 million shares outstanding.
The filing also discloses that the same fund recently sold 19,265 shares on 27 Jun 2025 for USD 133,121 and 6,422 shares on 30 Jun 2025 for USD 43,751, bringing total sales in the past three months to 25,687 shares (鈮� 0.07 % of the float) for gross proceeds of approximately USD 176,872.
The shares were originally acquired on 29 Mar 2021 via a cash-financed venture investment. No operational, earnings, or strategic updates are provided in this notice. Form 144 merely gives advance notice of potential affiliate sales; execution is not assured. Given the small size relative to the public float, the filing is unlikely to materially affect liquidity or valuation but does indicate continued position trimming by an early investor.
Jaguar Health, Inc. (NASDAQ: JAGX) received SEC notice that its Form S-3 shelf registration statement (File No. 333-288202) became effective on June 27, 2025 at 4:00 p.m. ET. The effectiveness allows the company to register and potentially issue securities in the future without additional SEC review, streamlining capital-raising activities. No financial terms, transaction details, or earnings information were disclosed in the notice.
Acuren Corporation has filed an amended S-4 registration statement for a proposed merger with NV5 Global. Under the merger agreement dated May 14, 2025, NV5 stockholders will receive for each share: (1) Acuren common stock worth $13.00 (subject to exchange ratio adjustments) plus (2) $10.00 in cash. The merger consideration represents a 32% premium to NV5's 30-day VWAP as of May 14, 2025.
Key terms include:
- Post-merger ownership: Acuren stockholders ~60%, NV5 stockholders ~40%
- Exchange ratio adjustments with 10% collar: 1.3636 shares (floor) to 1.1157 shares (ceiling)
- Voting agreements secured from holders of 44.7% of Acuren shares and 16.7% of NV5 shares
- Special stockholder meetings scheduled for July 31, 2025
Both boards have unanimously approved the merger. Acuren is an emerging growth company expected to lose this status on January 1, 2026.
FAQ
What is the current stock price of Acuren (TIC)?
What is the market cap of Acuren (TIC)?
What core services does Acuren Corp offer?
How does Acuren Corp support industrial markets?
What is nondestructive testing (NDT) and why is it important?
How does the Rope Access Technician Solutions (RAT) service work?
Why is lab testing a critical component of Acuren Corp's services?
How is Acuren Corp positioned within the competitive landscape?
What types of industries benefit from Acuren Corp's services?
What role does technical expertise play at Acuren Corp?
How does Acuren Corp maintain compliance and safety standards?
What distinguishes Acuren Corp in the realm of asset integrity services?
